AC
INFI

Ascend Capital’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Ascend Capital’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-250,000
Closed -$334K – 172
2016
Q2 		$334K Buy
+250,000
New +$1.17M 0.02% 137

Other funds holding INFI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ascend Capital's INFI Position: Q3 2016 in Review

Ascend Capital sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q3 2016, closing a stake of 250,000 shares — an estimated $334K sold.

Ascend Capital first reported a position in INFI in Q2 2016 and held it in 1 quarter. The position peaked at $334K in Q2 2016. 99 funds tracked by Wall St. Rank hold INFI as of Q3 2016.

  • Ascend Capital reported no remaining Infinity Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
  • Ascend Capital sold 250,000 Infinity Pharmaceuticals, Inc. shares in Q3 2016, an estimated $334K.
  • Ascend Capital first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2016 and held it in 1 quarter.
  • Ascend Capital's Infinity Pharmaceuticals, Inc. position peaked at $334K in Q2 2016.
  • 99 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q3 2016.

Based on Ascend Capital's 13F filing for Q3 2016, filed 14 Nov 2016.